168 related articles for article (PubMed ID: 25045534)
1. Prognostic factors and survival in patients treated surgically for recurrent metastatic uterine leiomyosarcoma.
Hoang HL; Ensor K; Rosen G; Leon Pachter H; Raccuia JS
Int J Surg Oncol; 2014; 2014():919323. PubMed ID: 25045534
[TBL] [Abstract][Full Text] [Related]
2. Surgical resection of pulmonary and extrapulmonary recurrences of uterine leiomyosarcoma.
Leitao MM; Brennan MF; Hensley M; Sonoda Y; Hummer A; Bhaskaran D; Venkatraman E; Alektiar K; Barakat RR
Gynecol Oncol; 2002 Dec; 87(3):287-94. PubMed ID: 12468327
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors and survival in patients treated surgically for primary and recurrent uterine leiomyosarcoma: a single center experience.
Bacalbasa N; Balescu I; Dima S; Brasoveanu V; Popescu I
Anticancer Res; 2015 Apr; 35(4):2229-34. PubMed ID: 25862883
[TBL] [Abstract][Full Text] [Related]
4. Secondary surgical resection for patients with recurrent uterine leiomyosarcoma.
Cybulska P; Sioulas V; Orfanelli T; Zivanovic O; Mueller JJ; Broach VA; Long Roche KC; Sonoda Y; Hensley ML; O'Cearbhaill RE; Chi DS; Alektiar KM; Abu-Rustum NR; Leitao MM
Gynecol Oncol; 2019 Aug; 154(2):333-337. PubMed ID: 31200927
[TBL] [Abstract][Full Text] [Related]
5. Leiomyosarcoma: One disease or distinct biologic entities based on site of origin?
Worhunsky DJ; Gupta M; Gholami S; Tran TB; Ganjoo KN; van de Rijn M; Visser BC; Norton JA; Poultsides GA
J Surg Oncol; 2015 Jun; 111(7):808-12. PubMed ID: 25920434
[TBL] [Abstract][Full Text] [Related]
6. Metastatic uterine leiomyosarcomas: a single-institution experience.
Bernstein-Molho R; Grisaro D; Soyfer V; Safra T; Merimsky O
Int J Gynecol Cancer; 2010 Feb; 20(2):255-60. PubMed ID: 20134269
[TBL] [Abstract][Full Text] [Related]
7. Uterine leiomyosarcoma: analysis of treatment failures and survival.
Gadducci A; Landoni F; Sartori E; Zola P; Maggino T; Lissoni A; Bazzurini L; Arisio R; Romagnolo C; Cristofani R
Gynecol Oncol; 1996 Jul; 62(1):25-32. PubMed ID: 8690287
[TBL] [Abstract][Full Text] [Related]
8. Uterine Sarcoma: Clinical Presentation, Treatment and Survival Outcomes in Thailand.
Potikul C; Tangjitgamol S; Khunnarong J; Srijaipracharoen S; Thavaramara T; Pataradool K
Asian Pac J Cancer Prev; 2016; 17(4):1759-67. PubMed ID: 27221849
[TBL] [Abstract][Full Text] [Related]
9. The influence of primary site on outcomes in leiomyosarcoma: a review of clinicopathologic differences between uterine and extrauterine disease.
Farid M; Ong WS; Tan MH; Foo LS; Lim YK; Chia WK; Soh LT; Poon D; Lee MJ; Ho ZC; Jeevan R; Chin F; Teo M; Quek R
Am J Clin Oncol; 2013 Aug; 36(4):368-74. PubMed ID: 22772425
[TBL] [Abstract][Full Text] [Related]
10. The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma.
Park JY; Park SK; Kim DY; Kim JH; Kim YM; Kim YT; Nam JH
Gynecol Oncol; 2011 Aug; 122(2):255-9. PubMed ID: 21565389
[TBL] [Abstract][Full Text] [Related]
11. Secondary cytoreduction in the management of recurrent uterine leiomyosarcoma.
Giuntoli RL; Garrett-Mayer E; Bristow RE; Gostout BS
Gynecol Oncol; 2007 Jul; 106(1):82-8. PubMed ID: 17434579
[TBL] [Abstract][Full Text] [Related]
12. Surgical cytoreduction in patients with metastatic uterine leiomyosarcoma at the time of initial diagnosis.
Leitao MM; Zivanovic O; Chi DS; Hensley ML; O'Cearbhaill R; Soslow RA; Barakat RR
Gynecol Oncol; 2012 May; 125(2):409-13. PubMed ID: 22366592
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes with intraoperative radiotherapy as a component of treatment for locally advanced or recurrent uterine sarcoma.
Barney BM; Petersen IA; Dowdy SC; Bakkum-Gamez JN; Haddock MG
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):191-7. PubMed ID: 21985942
[TBL] [Abstract][Full Text] [Related]
14. Comparison of current staging systems and a novel staging system for uterine leiomyosarcoma.
Giuntoli RL; Lessard-Anderson CR; Gerardi MA; Kushnir CL; Cliby WA; Metzinger DS; Gostout BS
Int J Gynecol Cancer; 2013 Jun; 23(5):869-76. PubMed ID: 23669444
[TBL] [Abstract][Full Text] [Related]
15. Pelvic radiation improves local control after hysterectomy for uterine leiomyosarcoma: a 20-year experience.
Mahdavi A; Monk BJ; Ragazzo J; Hunter MI; Lentz SE; Vasilev SA; Tewari KS
Int J Gynecol Cancer; 2009 Aug; 19(6):1080-4. PubMed ID: 19820372
[TBL] [Abstract][Full Text] [Related]
16. Secondary cytoreductive surgery in recurrent uterine leiomyosarcoma: a multi-institutional study.
Bizzarri N; Ghirardi V; Di Fiore GLM; De Iaco P; Gadducci A; Casarin J; Perrone AM; Pasciuto T; Scambia G; Fagotti A
Int J Gynecol Cancer; 2019 Sep; 29(7):1134-1140. PubMed ID: 31420411
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcome affected by tumor morcellation in unexpected early uterine leiomyosarcoma.
Lin KH; Torng PL; Tsai KH; Shih HJ; Chen CL
Taiwan J Obstet Gynecol; 2015 Apr; 54(2):172-7. PubMed ID: 25951723
[TBL] [Abstract][Full Text] [Related]
18. "Low-grade leiomyosarcoma" and late-recurring smooth muscle tumors of the uterus: a heterogenous collection of frequently misdiagnosed tumors associated with an overall favorable prognosis relative to conventional uterine leiomyosarcomas.
Veras E; Zivanovic O; Jacks L; Chiappetta D; Hensley M; Soslow R
Am J Surg Pathol; 2011 Nov; 35(11):1626-37. PubMed ID: 21921786
[TBL] [Abstract][Full Text] [Related]
19. Impact of adjuvant treatment and prognostic factors in stage I uterine leiomyosarcoma patients treated in Commission on Cancer®-accredited facilities.
Vaz J; Tian C; Richardson MT; Chan JK; Mysona D; Rao UN; Powell MA; Shriver CD; Hamilton CA; Casablanca Y; Maxwell GL; Darcy KM
Gynecol Oncol; 2020 Apr; 157(1):121-130. PubMed ID: 31954536
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors and survival of patients with uterine sarcoma: a German unicenter analysis.
Huss A; Klar M; Hasanov MF; Juhasz-Böss I; Bossart M
Arch Gynecol Obstet; 2023 Mar; 307(3):927-935. PubMed ID: 35780401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
